Atom | Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed)

Funder: National Institutes of Health

Funding Amounts: No budget cap; typical R01 duration up to 5 years; budgets must reflect actual project needs.

Summary: Supports research on how HIV-induced immunometabolic changes in cART-suppressed individuals increase risk and worsen outcomes of TB or HBV co-infection.

Key Information: Clinical trials are not allowed; foreign and domestic institutions are eligible; preliminary data required.

Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed)

Sign in to see full grant listing